175 related articles for article (PubMed ID: 27128609)
1. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Clin Pharmacol Drug Dev; 2014 May; 3(3):194-201. PubMed ID: 27128609
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Br J Clin Pharmacol; 2013 Feb; 75(2):440-9. PubMed ID: 22642721
[TBL] [Abstract][Full Text] [Related]
3. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Kadokura T; Kashiwa M; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Biopharm Drug Dispos; 2013 Nov; 34(8):431-41. PubMed ID: 23929659
[TBL] [Abstract][Full Text] [Related]
5. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
6. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
Kadokura T; Taniuchi Y; Inoue H; Saito M; Iwahana M; Yamada S; Urae A; Nakamura M
Int J Clin Pharmacol Ther; 2013 Mar; 51(3):200-6. PubMed ID: 23211396
[TBL] [Abstract][Full Text] [Related]
7. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
Bernard A; Vaccaro N; Acharya M; Jiao J; Monbaliu J; De Vries R; Stieltjes H; Yu M; Tran N; Chien C
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):63-73. PubMed ID: 27128004
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
Shaik MN; LaBadie RR; Rudin D; Levin WJ
Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
11. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
Hashimoto T; Suzuki K; Kihara Y; Iwatsubo T; Miyashita A; Heeringa M; Onkels H; Groenendaal D; Verheggen F; van Marle S; Usui T
Xenobiotica; 2013 Jun; 43(6):534-47. PubMed ID: 23167531
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
13. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
14. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
15. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
16. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
18. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG; Mehta SR; Jukema JW; Lip GY; Gibson CM; Kovar F; Kala P; Garcia-Hernandez A; Renfurm RW; Granger CB;
Eur Heart J; 2011 Oct; 32(20):2541-54. PubMed ID: 21878434
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole.
Ziesenitz VC; König SK; Mahlke NS; Skopp G; Haefeli WE; Mikus G
J Clin Pharmacol; 2015 Jun; 55(6):708-17. PubMed ID: 25651378
[TBL] [Abstract][Full Text] [Related]
20. The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.
Barve A; Kovacs SJ; Ke J; Crabbe R; Grosgurin P; Menetrey A; Nicolas-Métral V; Dabovic K; Dole K; Zhang J; Praestgaard J; Sunkara G; Stein D
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):25-32. PubMed ID: 27128001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
